Elagolix: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Elagolix. Educational only — not medical advice.
Labeled uses
ORIAHNN is indicated for the management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women. Limitation of Use: Use of ORIAHNN should be limited to 24 months due to the risk of continued bone loss, which may not be reversible [see Dosage and Administration ( 2.1 ) and Warnings and Precautions ( 5.2 ) ] .
Source: FDA labeling via NIH DailyMed (set 99f6eee7…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.